Methicillin-Resistant Staphylococcus aureus- Pharmacist


  Credits  1.5

This product is currently out of stock and unavailable.

Staphylococcus aureus is a leading cause of infection in both the community and hospital settings. A highly virulent and hardy pathogen, it is notable for its ability to cause a wide variety of infections, ranging from simple skin and soft tissue infections (SSTIs) to life-threatening infections such as osteomyelitis and sepsis. Staphylococcus aureus is broadly subdivided into methicillin-sensitive Staphylococcus aureus (MSSA) and methicillin-resistant Staphylococcus aureus (MRSA). A common misconception among both clinicians and the general public is that MRSA causes more severe infections than MSSA. In reality, both organisms cause the same general types of infections, including life-threatening infections. However, from a drug therapy perspective, MRSA manifests a higher degree of antimicrobial resistance than MSSA, making treatment a challenge in both the outpatient and inpatient settings. For many years, MRSA was considered a nosocomial pathogen, primarily encountered in large, tertiary healthcare institutions. However, over the last 2 decades, there has been a dramatic increase in the incidence of MRSA infections in community and outpatient settings. Infections originating in these settings are commonly called community-associated methicillin-resistant Staphylococcus aureus (CA-MRSA) infections; those originating in the hospital or other healthcare settings (eg, skilled nursing facilities) are generally termed healthcare-associated methicillin-resistant Staphylococcus aureus (HA-MRSA) infections. This issue will review important concepts related to MRSA infections, with a focus on CA-MRSA. Important management strategies, including new antibiotics used in the treatment of MRSA, will be highlighted. With the increasing incidence of CA-MRSA infections, as well as a global increase in antimicrobial resistance in this pathogen, community providers play an important role in educating both patients and other providers about appropriate treatment options.


Subscribe and Save. Get access to this course PLUS the Rx Resource Library!

Explore Our Subscription Options

Course Information

Target Audience

Pharm/Nurse Drug Therapy

Knowledge Level

General Overview

This activity will apply to a broad range of learning needs/pharmacy settings. It may include common disease state/therapy overivews and/or general pharmacy needs such as medication errors, immunizations, or law topics.

Learning Objectives

Course Accreditation

  • Activity Type:
  • CE Broker
  • Universal Activity Number:
    Pharmacist : 0428-0000-15-001-H01-P
PharmCon is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education.

PharmCon, Inc. is an approved course provider for continuing education for nurses by the Florida Board of Nursing. PharmCon is also recognized by the California Board of Nursing as a provider of nursing programs.

In order to obtain a Statement of Credit, attendees must answer poll questions where presented and complete a program evaluation. Attendees may immediately print their Statement of Credit or leave them stored on the website.

Technology Requirements

  • Hardware Requirements
    Standard Windows/Mac System
    iPad or iPhone
    Minimum screen resolution: 1024x768
    Speakers or headphones
  • Software Requirements
    Standard Windows/Mac System
    iPad or iPhone
    Minimum screen resolution: 1024x768
    Speakers or headphones
  • Network Requirements
    Broadband Internet Connection:
    T1, Hi-speed DSL or Cable
    4G cellular connection
Computer sharing is NOT permitted due to accreditation guidelines on activity monitoring. Credit is earned by one user per device.